Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li - Signal transduction and targeted therapy, 2021 - nature.com
Melanoma is the most lethal skin cancer that originates from the malignant transformation of
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
melanocytes. Although melanoma has long been regarded as a cancerous malignancy with …
Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma
CU Blank, MW Lucas, RA Scolyer… - The New England …, 2024 - research.rug.nl
BACKGROUND: Phase 1-2 trials involving patients with resectable, macroscopic stage III
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …
melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant …
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial
ILM Reijers, AM Menzies, ACJ Van Akkooi… - Nature medicine, 2022 - nature.com
Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in
clinical stage III nodal melanoma, and pathologic response is strongly associated with …
clinical stage III nodal melanoma, and pathologic response is strongly associated with …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double …
Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a …
JS Weber, MS Carlino, A Khattak, T Meniawy… - The Lancet, 2024 - thelancet.com
Background Checkpoint inhibitors are standard adjuvant treatment for stage IIB–IV resected
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …
melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 …
Endocrine toxicities of immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …
pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T …
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
EA Rozeman, EP Hoefsmit, ILM Reijers, RPM Saw… - Nature medicine, 2021 - nature.com
Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …
patients with macroscopic stage III melanoma in the phase 1b OpACIN (NCT02437279) and …